Clal Biotechnology Industries
This article was originally published in Start Up
Executive Summary
Clal Biotechnology Industries Ltd. was set up a year ago as a subsidiary of Israel's second largest conglomerate, Clal, to invest in young biotech and pharmaceutical companies. The fund does mezzanine and mid-stage financing. Led by David Haselkorn, PhD, it has raised $100 million from Clal and outside investors and to date has invested $27 million in three companies, all Israeli.